- Home
- INTU vs MRNA Comparison
INTU vs MRNA Comparison
Compare INTU & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | MRNA |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.8B | 91.2B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INTU | MRNA |
|---|---|---|
| Price | $344.97 | $249.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 34 | 23 |
| Target Price | ★ $407.89 | $158.47 |
| AVG Volume (30 Days) | 2.8M | ★ 13.9M |
| Earning Date | 11-19-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | 20.41 | ★ 21.77 |
| EPS | ★ 16.46 | N/A |
| Revenue | ★ $21,448,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $9.15 | $24.04 |
| Revenue Next Year | $9.05 | $10.63 |
| P/E Ratio | $20.91 | ★ N/A |
| Revenue Growth | ★ 13.90 | 4.29 |
| 52 Week Low | $252.84 | $22.28 |
| 52 Week High | $682.27 | $280.80 |
Technical Indicators
Market Signals| Indicator | INTU | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 58.77 |
| Support Level | $320.79 | $45.39 |
| Resistance Level | $365.16 | $254.48 |
| Average True Range (ATR) | 12.74 | 20.18 |
| MACD | -0.62 | 1.45 |
| Stochastic Oscillator | 53.89 | 68.94 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.